InterMune Receives Average Rating of “Buy” from Analysts (NASDAQ:ITMN)
InterMune (NASDAQ:ITMN) has been given a consensus rating of “Buy” by the fifteen brokerages that are covering the stock, Stock Ratings News reports. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and nine have assigned a buy rating to the company. The average 1-year target price among brokers that have issued ratings on the stock in the last year is $44.85.
In other InterMune news, CEO Daniel G. Welch unloaded 171,025 shares of the stock on the open market in a transaction dated Thursday, August 7th. The stock was sold at an average price of $44.98, for a total value of $7,692,704.50. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.
InterMune (NASDAQ:ITMN) opened at 43.08 on Thursday. InterMune has a 52 week low of $10.95 and a 52 week high of $47.72. The stock has a 50-day moving average of $43.93 and a 200-day moving average of $33.60. The company’s market cap is $4.274 billion.
InterMune (NASDAQ:ITMN) last announced its earnings results on Wednesday, August 6th. The company reported ($0.72) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.56) by $0.16. The company had revenue of $35.70 million for the quarter, compared to the consensus estimate of $33.96 million. During the same quarter in the prior year, the company posted ($0.77) earnings per share. The company’s quarterly revenue was up 141.2% on a year-over-year basis. Analysts expect that InterMune will post $-2.73 EPS for the current fiscal year.
Several analysts have recently commented on the stock. Analysts at William Blair raised their price target on shares of InterMune from $48.00 to $55.00 in a research note on Friday. Separately, analysts at Stifel Nicolaus raised their price target on shares of InterMune from $51.00 to $53.00 in a research note on Thursday. They now have a “buy” rating on the stock. Finally, analysts at Robert W. Baird raised their price target on shares of InterMune from $44.00 to $50.00 in a research note on Thursday.
InterMune, Inc (NASDAQ:ITMN) is a biotechnology company focused on the research, development and commercialization of therapies in pulmonology and orphan fibrotic diseases.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.